Jane Street Group LLC Grows Stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Jane Street Group LLC lifted its holdings in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 4.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 133,405 shares of the company’s stock after buying an additional 6,221 shares during the quarter. Jane Street Group LLC owned about 1.91% of Global X Genomics & Biotechnology ETF worth $1,295,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of GNOM. SBI Securities Co. Ltd. purchased a new stake in Global X Genomics & Biotechnology ETF during the 4th quarter worth about $50,000. Oxinas Partners Wealth Management LLC purchased a new stake in Global X Genomics & Biotechnology ETF during the 4th quarter worth about $103,000. Sanctuary Advisors LLC purchased a new stake in Global X Genomics & Biotechnology ETF in the 4th quarter worth approximately $104,000. Sei Investments Co. purchased a new stake in Global X Genomics & Biotechnology ETF in the 4th quarter worth approximately $114,000. Finally, Smartleaf Asset Management LLC lifted its stake in Global X Genomics & Biotechnology ETF by 11.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 12,604 shares of the company’s stock worth $122,000 after purchasing an additional 1,265 shares in the last quarter. 56.95% of the stock is currently owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Price Performance

NASDAQ GNOM opened at $7.98 on Wednesday. Global X Genomics & Biotechnology ETF has a 1 year low of $6.80 and a 1 year high of $11.88. The stock has a market capitalization of $48.36 million, a PE ratio of -3.41 and a beta of 1.03. The company’s 50 day simple moving average is $7.94 and its two-hundred day simple moving average is $9.27.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.